Juvenile Idiopathic arthritis (JIA) - Market Insight, Epidemiology and Market Forecast - 2028

January 2019 | 100 pages | ID: J329AFF9F78EN
DelveInsight

Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's 'Juvenile Idiopathic arthritis (JIA) - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Juvenile Idiopathic arthritis (JIA) epidemiology and market outlook for the 7MM.

MARKETS COVERED

• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Juvenile Idiopathic arthritis (JIA) Understanding and Treatment Algorithm

The market report provides the overview of the Juvenile Idiopathic arthritis (JIA) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Juvenile Idiopathic arthritis (JIA) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Juvenile Idiopathic arthritis (JIA) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Juvenile Idiopathic arthritis (JIA) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Juvenile Idiopathic arthritis (JIA) Market Outlook

The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Juvenile Idiopathic arthritis (JIA) market.
Juvenile Idiopathic arthritis (JIA) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Juvenile Idiopathic arthritis (JIA) Report Insights

• Patient Population in Juvenile Idiopathic arthritis (JIA)
• Therapeutic Approaches in Juvenile Idiopathic arthritis (JIA)
• Juvenile Idiopathic arthritis (JIA) Pipeline Analysis
• Juvenile Idiopathic arthritis (JIA) Market Size and Trends
• Juvenile Idiopathic arthritis (JIA) Market Opportunities
• Impact of upcoming Therapies in Juvenile Idiopathic arthritis (JIA)

Juvenile Idiopathic arthritis (JIA) Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Juvenile Idiopathic arthritis (JIA) Report Assessment

• Current Treatment Practices in Juvenile Idiopathic arthritis (JIA)
• Unmet Needs in Juvenile Idiopathic arthritis (JIA)
• Market Attractiveness
• Market Drivers and Barriers

KEY BENEFITS

• The report will help to develop Business Strategies by understanding the trends shaping and driving the Juvenile Idiopathic arthritis (JIA) market
• Organize sales and marketing efforts by identifying the best opportunities for Juvenile Idiopathic arthritis (JIA) market
• To understand the future market competition in the Juvenile Idiopathic arthritis (JIA) market.

Contents

1. REPORT INTRODUCTION

2. JUVENILE IDIOPATHIC ARTHRITIS (JIA) MARKET OVERVIEW AT A GLANCE

2.1. Market Share Distribution of Juvenile Idiopathic arthritis (JIA) in 2016
2.2. Market Share Distribution of Juvenile Idiopathic arthritis (JIA) in 2028

3. DISEASE BACKGROUND AND OVERVIEW: JUVENILE IDIOPATHIC ARTHRITIS (JIA)

3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Juvenile Idiopathic arthritis (JIA) in 7MM
4.3. Total Prevalent Patient Population of Juvenile Idiopathic arthritis (JIA) in 7MM – By Countries

5. EPIDEMIOLOGY OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) BY COUNTRIES

5.1. United States
  5.1.1. Assumptions and Rationale
  5.1.2. Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA)
  5.1.3. Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA)
  5.1.4. Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA)
  5.1.5. Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA)
  5.1.6. Treatable Cases of the Juvenile Idiopathic arthritis (JIA)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
  5.4.1. Assumptions and Rationale
  5.4.2. Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA)
  5.4.3. Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA)
  5.4.4. Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA)
  5.4.5. Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA)
  5.4.6. Treatable Cases of the Juvenile Idiopathic arthritis (JIA)
5.5. France
  5.5.1. Assumptions and Rationale
  5.5.2. Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA)
  5.5.3. Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA)
  5.5.4. Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA)
  5.5.5. Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA)
  5.5.6. Treatable Cases of the Juvenile Idiopathic arthritis (JIA)
5.6. Italy
  5.6.1. Assumptions and Rationale
  5.6.2. Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA)
  5.6.3. Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA)
  5.6.4. Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA)
  5.6.5. Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA)
  5.6.6. Treatable Cases of the Juvenile Idiopathic arthritis (JIA)
5.7. Spain
  5.7.1. Assumptions and Rationale
  5.7.2. Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA)
  5.7.3. Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA)
  5.7.4. Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA)
  5.7.5. Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA)
  5.7.6. Treatable Cases of the Juvenile Idiopathic arthritis (JIA)
5.8. United Kingdom
  5.8.1. Assumptions and Rationale
  5.8.2. Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA)
  5.8.3. Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA)
  5.8.4. Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA)
  5.8.5. Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA)
  5.8.6. Treatable Cases of the Juvenile Idiopathic arthritis (JIA)
5.9. Japan
  5.9.1. Assumptions and Rationale
  5.9.2. Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA)
  5.9.3. Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA)
  5.9.4. Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA)
  5.9.5. Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA)
  5.9.6. Treatable Cases of the Juvenile Idiopathic arthritis (JIA)

6. CURRENT TREATMENT & MEDICAL PRACTICES

6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. UNMET NEEDS OF THE JUVENILE IDIOPATHIC ARTHRITIS (JIA)

8. MARKETED THERAPIES

8.1. Drug A: Company
  8.1.1. Drug Description
  8.1.2. Mechanism of Action
  8.1.3. Regulatory Milestones
  8.1.4. Advantages & Disadvantages
  8.1.5. Product Profile
8.2. Drug B: Company
  8.2.1. Drug Description
  8.2.2. Mechanism of Action
  8.2.3. Regulatory Milestones
  8.2.4. Advantages & Disadvantages
  8.2.5. Product Profile

9. PIPELINE THERAPIES – AT A GLANCE

10. KEY CROSS COMPETITION

11. EMERGING THERAPIES FOR JUVENILE IDIOPATHIC ARTHRITIS (JIA)

11.1. Drug C: Company
  11.1.1. Drug Description
  11.1.2. Clinical Trials Details
  11.1.3. Safety and Efficacy Profile
  11.1.4. Advantages & Disadvantages
  11.1.5. Pipeline Development Activities
  11.1.6. Product Profile
11.2. Drug D: Company
  11.2.1. Drug Description
  11.2.2. Clinical Trials Details
  11.2.3. Safety and Efficacy Profile
  11.2.4. Advantages & Disadvantages
  11.2.5. Pipeline Development Activities
  11.2.6. Product Profile

12. JUVENILE IDIOPATHIC ARTHRITIS (JIA): 7MM MARKET ANALYSIS

12.1. 7MM Market Size of Juvenile Idiopathic arthritis (JIA)
12.2. 7MM Percentage Share of drugs marketed for Juvenile Idiopathic arthritis (JIA)
12.3. 7MM Market Sales of Juvenile Idiopathic arthritis (JIA) by Products

13. JUVENILE IDIOPATHIC ARTHRITIS (JIA): COUNTRY-WISE MARKET ANALYSIS

13.1. United States
  13.1.1. Market Size of Juvenile Idiopathic arthritis (JIA) in United States
  13.1.2. Percentage Share of drugs marketed for Juvenile Idiopathic arthritis (JIA) in United States
  13.1.3. Market Sales of Juvenile Idiopathic arthritis (JIA) by Products in United States
  13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
  13.2.1. Germany
    13.2.1.1. Market Size of Juvenile Idiopathic arthritis (JIA) in Germany
    13.2.1.2. Percentage Share of drugs marketed for Juvenile Idiopathic arthritis (JIA) in Germany
    13.2.1.3. Market Sales of Juvenile Idiopathic arthritis (JIA) by Products in Germany
    13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.2. France
    13.2.2.1. Market Size of Juvenile Idiopathic arthritis (JIA) in France
    13.2.2.2. Percentage Share of drugs marketed for Juvenile Idiopathic arthritis (JIA) in France
    13.2.2.3. Market Sales of Juvenile Idiopathic arthritis (JIA) by Products in France
    13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.3. Italy
    13.2.3.1. Market Size of Juvenile Idiopathic arthritis (JIA) in Italy
    13.2.3.2. Percentage Share of drugs marketed for Juvenile Idiopathic arthritis (JIA) in Italy
    13.2.3.3. Market Sales of Juvenile Idiopathic arthritis (JIA) by Products in Italy
    13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.4. Spain
    13.2.4.1. Market Size of Juvenile Idiopathic arthritis (JIA) in Spain
    13.2.4.2. Percentage Share of drugs marketed for Juvenile Idiopathic arthritis (JIA) in Spain
    13.2.4.3. Market Sales of Juvenile Idiopathic arthritis (JIA) by Products in Spain
    13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.5. United Kingdom
    13.2.5.1. Market Size of Juvenile Idiopathic arthritis (JIA) in United Kingdom
    13.2.5.2. Percentage Share of drugs marketed for Juvenile Idiopathic arthritis (JIA) in United Kingdom
    13.2.5.3. Market Sales of Juvenile Idiopathic arthritis (JIA) by Products in United Kingdom
    13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
  13.3.1. Market Size of Juvenile Idiopathic arthritis (JIA) in Japan
  13.3.2. Percentage Share of drugs marketed for Juvenile Idiopathic arthritis (JIA) in Japan
  13.3.3. Market Sales of Juvenile Idiopathic arthritis (JIA) by Products in Japan
  13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. MARKET DRIVERS

15. MARKET BARRIERS

16. APPENDIX

17. REPORT METHODOLOGY

17.1. Sources

18. DELVEINSIGHT CAPABILITIES

19. DISCLAIMER

20. ABOUT DELVEINSIGHT

Indication Specific

List Of Tables

LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in 7MM
Table 2: Total Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in United States (2016-2028)
Table 6: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in United States (2016-2028)
Table 7: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in Germany (2016-2028)
Table 12: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in France (2016-2028)
Table 15: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in France (2016-2028)
Table 16: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in France (2016-2028)
Table 17: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in Italy (2016-2028)
Table 22: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in Spain (2016-2028)
Table 27: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in UK (2016-2028)
Table 31: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in UK (2016-2028)
Table 32: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in Japan (2016-2028)
Table 37: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Table 42:7MM- Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Table 45: United States-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Table 48: Germany-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Table 51: France-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Table 54: Italy-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Table 57: Spain-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Table 60:UK-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Table 63: Japan-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)

List Of Figures

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in United States (2016-2028)
Figure 7: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in Germany (2016-2028)
Figure 12: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in France (2016-2028)
Figure 16: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in France (2016-2028)
Figure 17: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in Italy (2016-2028)
Figure 22: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in Spain (2016-2028)
Figure 27: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in UK (2016-2028)
Figure 32: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Juvenile Idiopathic arthritis (JIA) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Juvenile Idiopathic arthritis (JIA) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Juvenile Idiopathic arthritis (JIA) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Juvenile Idiopathic arthritis (JIA) in Japan (2016-2028)
Figure 37: Treatable Cases of the Juvenile Idiopathic arthritis (JIA) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Figure 42:7MM- Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Figure 45: United States-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Figure 48: Germany-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Figure 51: France-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Figure 54: Italy-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Figure 57: Spain-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Figure 60:UK-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Juvenile Idiopathic arthritis (JIA) in USD MM (2016-2028)
Figure 63: Japan-Market Share Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Juvenile Idiopathic arthritis (JIA) by Therapies in USD MM (2016-2028)